Indian Health Minister Asks Novartis to Stand Down On Gleevec Patent Fight
This article was originally published in The Pink Sheet Daily
Executive Summary
Indian regulators threaten compulsory licensing of the oncologic, but Novartis says it has no plans to end its bid for patent protection.